Bridge Realization Estimate
ML model predicts what fraction of the bridge is achievable (accuracy: 60%, n=5,839)
Expected realization: 62% of modeled bridge. Strengths: Bed Count. Risks: Occupancy Rate. Risk-adjusted uplift: $2.4M (vs $3.9M modeled).
EBITDA Bridge — 7 RCM Levers
Each bar shows the annual EBITDA impact at full run-rate. Revenue levers increase top-line; cost levers reduce operating expense; cash acceleration releases working capital. Calibrated to published research bands (Denial 12%→5% = $8-15M on $400M NPR).
Lever Detail
Each value shows its data source. SELLER = seller data room, DEFAULT = model default, BENCHMARK = P75 peer benchmark.
| Lever | Current | Target | Revenue | Cost | EBITDA | WC | Ramp |
|---|---|---|---|---|---|---|---|
| Cost to Collect | 4.5% DEFAULT | 2.5% BENCHMARK | $0 | $1.5M | $1.5M | $0 | 12mo |
| Denial Rate Reduction | 12.0% DEFAULT | 6.5% BENCHMARK | $1.4M | $41K | $1.5M | $0 | 12mo |
| A/R Days Reduction | 52.00 DEFAULT | 38.00 BENCHMARK | $228K | $677K | $905K | $2.9M | 9mo |
| Clean Claim Rate | 88.0% DEFAULT | 96.0% BENCHMARK | $0 | $48K | $48K | $0 | 6mo |
| Net Collection Rate | 93.5% DEFAULT | 42.5% BENCHMARK | $0 | $0 | $0 | $0 | 18mo |
| CDI / Case Mix Index | 135.0% DEFAULT | 142.0% BENCHMARK | $0 | $0 | $0 | $0 | 18mo |
Implementation Timing Curve
Linear ramp to full run-rate per lever. Month 0 = close date. Partners should expect 60-70% of total uplift realized by month 12.
| Lever | M0 | M3 | M6 | M9 | M12 | M18 | M24 | M36 |
|---|---|---|---|---|---|---|---|---|
| Cost to Collect | $0 | $372K | $744K | $1.1M | $1.5M | $1.5M | $1.5M | $1.5M |
| Denial Rate Reduction | $0 | $368K | $736K | $1.1M | $1.5M | $1.5M | $1.5M | $1.5M |
| A/R Days Reduction | $0 | $302K | $603K | $905K | $905K | $905K | $905K | $905K |
| Clean Claim Rate | $0 | $24K | $48K | $48K | $48K | $48K | $48K | $48K |
| Cumulative | $0 | $1.1M | $2.1M | $3.2M | $3.9M | $3.9M | $3.9M | $3.9M |
Returns Sensitivity (IRR / MOIC)
5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Green = exceeds 20% IRR hurdle. Amber = 15-20%. Red = below hurdle or loss. RCM uplift of $3.9M is added at exit.
| Entry \ Exit | 9.0x | 10.0x | 11.0x | 11.5x | 12.0x |
|---|---|---|---|---|---|
| 8.0x | 60% / 10.5x | 65% / 12.1x | 69% / 13.6x | 70% / 14.4x | 72% / 15.1x |
| 9.0x | 55% / 9.0x | 60% / 10.4x | 64% / 11.7x | 65% / 12.4x | 67% / 13.1x |
| 10.0x | 51% / 7.8x | 55% / 9.0x | 59% / 10.2x | 61% / 10.8x | 63% / 11.4x |
| 11.0x | 47% / 6.8x | 51% / 7.9x | 55% / 9.0x | 57% / 9.6x | 59% / 10.1x |
| 12.0x | 43% / 5.9x | 47% / 7.0x | 51% / 8.0x | 53% / 8.5x | 55% / 9.0x |
Covenant Headroom (at 10x Entry, 6.5x Max Leverage)
Pro forma EBITDA can decline 25% before the 6.5x covenant trips. RCM uplift reduces leverage from 8.5x to 4.9x, adding 3.6 turns of cushion.
5-Year Value Creation Waterfall
EBITDA trajectory: 3% organic growth + RCM uplift ramp (full run-rate at month 18).
| Base EBITDA | RCM Uplift | Total | Margin | |
|---|---|---|---|---|
| Entry | $5.4M | — | $5.4M | 7.3% |
| Year 1 | $5.6M | +$2.6M | $8.2M | 11.0% |
| Year 2 | $5.7M | +$3.9M | $9.6M | 13.0% |
| Year 3 | $5.9M | +$3.9M | $9.8M | 13.2% |
| Year 4 | $6.1M | +$3.9M | $10.0M | 13.4% |
| Year 5 | $6.3M | +$3.9M | $10.2M | 13.7% |
Achievement Sensitivity
What if we only achieve a fraction of each lever? 50% = conservative, 75% = base management case, 100% = plan, 120% = stretch.
| Lever | 50% | 75% | 100% | 120% |
|---|---|---|---|---|
| Cost to Collect | $744K | $1.1M | $1.5M | $1.8M |
| Denial Rate Reductio | $736K | $1.1M | $1.5M | $1.8M |
| A/R Days Reduction | $453K | $679K | $905K | $1.1M |
| Clean Claim Rate | $24K | $36K | $48K | $57K |
| Total | $2.0M | $2.9M | $3.9M | $4.7M |
Peer Context — Where This Hospital Sits
Key metrics vs 19 size-matched peers. Low percentile on margin/efficiency metrics = more room for improvement = larger bridge opportunity.
| Metric | Hospital | P25 | P50 | P75 | Percentile |
|---|---|---|---|---|---|
| Op Margin | 7.3% | -10.1% | -8.8% | 7.2% | P74 |
| Net-to-Gross | 32.8% | 29.7% | 37.4% | 42.5% | P37 |
| Occupancy | 23.1% | 40.6% | 45.7% | 58.0% | P5 |
| Rev/Bed | $1.2M | $1.6M | $1.8M | $2.6M | P16 |
| Exp/Bed | $1.1M | $1.4M | $2.0M | $2.7M | P11 |
Bridge Methodology
Coefficients calibrated to published research bands: denial 12%→5% = $8-15M on $400M NPR. Current metrics estimated from HCRIS public data and ML predictions. Target metrics set at P75 peer benchmarks with 60% gap closure assumption. Revenue levers use NPR × delta × avoidable share. Cost levers use claims volume × cost per reworked claim. Working capital from AR reduction is one-time cash (not included in recurring EBITDA). Returns assume 5.5x leverage, 3% organic growth, 10%/yr debt paydown.